top of page
v-2.jpg

About Us

Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.  

Leadership Team

treating inflammation at the source(16).png

Matthew A. Gonda, Ph.D.

President, CEO and Founder

treating inflammation at the source(16).png

Randall B. Riggs, MBA

Chief Business Officer

treating inflammation at the source(16).png

Shima Joshi, Ph.D.

VP, Regulatory Affairs

treating inflammation at the source(16).png

Vernon L. Alvarez, Ph.D.

SVP, Research & Development

treating inflammation at the source(16).png

Satish Joshi, Ph.D.

VP, Peptide Chemistry

treating inflammation at the source(16).png

Danny O. Helton, Ph.D.

VP, Chemistry & Manufacturing

Board of Directors 

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Lawrence W. Greer, DDS, MBA

Director

G. William Coble, II

Director

Daniel D. Canale, M.D.

Director

Thomas G. Andrews

Director and Founder

Dennis J. Carlo, Ph.D.

Director

Raymond Pirtle, Jr.

Director

Founders

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Thomas G. Andrews

Director and Founder

Jacek Hawiger, M.D., Ph.D.

Founder

bottom of page